Publications Response to Placebo, Measured by Endoscopic Evaluation of Crohn’s Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials Citation Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clin Gastroenterol Hepatol. 2020 May;18(5):1121-1132.e2. doi: 10.1016/j.cgh.2019.08.025. Epub 2019 Aug 20. PMID: 31442599. Abstract Background & aims: Endoscopy is used to measure activity of Crohn’s disease (CD) and determine eligibility and outcomes of participants in randomized controlled trials of therapeutic agents. We aimed to estimate the rate of response to placebo in trials, based on endoscopic evaluation of CD activity, and identify factors that affect this response. Tags Crohn's Disease, Drug Therapy, Endoscopy, Observational Studies, Placebo Effect, TNF Treatment, Trial Design, Ustekinumab Read More
